<code id='30EFE7B8CB'></code><style id='30EFE7B8CB'></style>
    • <acronym id='30EFE7B8CB'></acronym>
      <center id='30EFE7B8CB'><center id='30EFE7B8CB'><tfoot id='30EFE7B8CB'></tfoot></center><abbr id='30EFE7B8CB'><dir id='30EFE7B8CB'><tfoot id='30EFE7B8CB'></tfoot><noframes id='30EFE7B8CB'>

    • <optgroup id='30EFE7B8CB'><strike id='30EFE7B8CB'><sup id='30EFE7B8CB'></sup></strike><code id='30EFE7B8CB'></code></optgroup>
        1. <b id='30EFE7B8CB'><label id='30EFE7B8CB'><select id='30EFE7B8CB'><dt id='30EFE7B8CB'><span id='30EFE7B8CB'></span></dt></select></label></b><u id='30EFE7B8CB'></u>
          <i id='30EFE7B8CB'><strike id='30EFE7B8CB'><tt id='30EFE7B8CB'><pre id='30EFE7B8CB'></pre></tt></strike></i>

          leisure time

          leisure time

          author:hotspot    Page View:87158
          Illustration of a hospital bed with a spotlight above and money below. -- health tech coverage from STAT
          Adobe

          General Catalyst’s plan to take over a hospital in the coming months could be the first of many such deals, driven by financially strained hospitals looking for saviors, and venture capitalists convinced that they have the technology solutions for fixing the health care sector’s vexing problems.

          The venture firm announced plans in October to acquire a health system and then use it as a proving ground for technology that its portfolio companies sell, including generative artificial intelligence-powered solutions applied to health care problems. The move — a result of industry-wide frustration with health systems’ risk aversion and hesitation to adopt new technology — also comes at a time when health tech startups that raised millions of venture dollars during the pandemic’s early stages are now scrambling to find customers.

          advertisement

          Given workforce shortages, clinician burnout, rising drug costs, and a surging aging population, “it’s not that big a leap to say that more such purchases are going to occur,” said Robert Klitzman, a Columbia psychiatry professor and director of its bioethics masters program. “Hospitals are in a very tough spot,” he said, adding, “There may be hospitals that think, ‘Oh, great, someone wants to buy us.’”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Average age of first period drops to 11.9 years, study shows
          Average age of first period drops to 11.9 years, study shows

          AdobeMenstruationisacriticalindicatorofhealth.Whetherandwhensomeonewithauterusgetstheirperiod—forthe

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          The 10 drugs up first for Medicare price negotiation

          PresidentBiden'sWhiteHouseannouncedthefirst10medicinesthatwillbeupfirstinitsnewdrugpricenegotiationp